Ginkgo Bioworks DNA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$76.06M+5.8% | -$80.75M0.0% | -$80.76M-33.9% | -$60.3M+33.7% | -$90.96M+15.4% | ||
| $12.8M-6.3% | $13.66M-3.6% | $14.17M-13.3% | $16.34M+10.2% | $14.82M-5.3% | ||
| $15.85M-24.6% | $21.03M+17.9% | $17.84M-29.5% | $25.29M+45.5% | $17.39M-15.4% | ||
| —— | -$341K0.0% | -$341K0.0% | -$341K0.0% | -$341K-45.7% | ||
| $242K-86.7% | $1.82M+340% | -$757K— | —— | $667K— | ||
| -$11.6M— | —— | $22.12M+258% | -$13.99M-258% | $8.87M+195% | ||
| -$94K+71.9% | -$334K— | —— | —— | $167K-86.1% | ||
| -$758K-111% | $7M— | $0-100% | $5.16M— | $0-100% | ||
| -$185K+59.2% | -$453K+71.1% | -$1.57M— | $0+100% | -$149K+73.8% | ||
| -$2.61M+49.7% | -$5.18M-46.7% | -$3.53M+66.3% | -$10.49M+20.5% | -$13.19M-1,423% | ||
| $7.11M-6.8% | $7.63M+0.7% | $7.58M+1.3% | $7.49M+1.5% | $7.38M-1.3% | ||
| -$5M+45.3% | -$9.14M-27.7% | -$7.16M-4.5% | -$6.85M-43.0% | -$4.79M-36.9% | ||
| -$46.69M+2.1% | -$47.68M-50.9% | -$31.61M+21.5% | -$40.25M+21.9% | -$51.52M-21.4% | ||
| $1.93M+38,560% | $5K— | $0-100% | $38K-99.5% | $7.62M-44.4% | ||
| $83.16M+395% | $16.79M-79.4% | $81.71M-36.6% | $128.95M-32.6% | $191.18M— | ||
| $108.18M+318% | $25.9M+140% | -$64.96M-200% | $64.96M— | $0+100% | ||
| -$48K— | —— | -$249K-75.4% | -$142K-18.3% | -$120K— | ||
| $23.13M— | —— | -$72.82M-14.0% | -$63.89M+67.8% | -$198.68M-1,418% | ||
| $19K-24.0% | $25K+4.2% | $24K-75.5% | $98K-52.7% | $207K+2.0% | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$19K-100% | $8.14M-18.1% | $9.94M+10,241% | -$98K+52.7% | -$207K-2.0% | ||
| -$129K— | —— | $93K-50.0% | $186K+151% | $74K+201% | ||
| -$23.7M— | —— | -$94.39M+9.3% | -$104.05M+58.4% | -$250.34M-349% | ||
| $0— | —— | —— | $2.93M+125% | $1.3M— | ||
| -$253K— | —— | —— | —— | -$8.77M— | ||
| -$1.21M— | —— | —— | -$265K+92.8% | -$3.69M— | ||
| -$5M+45.3% | -$9.14M-27.7% | -$7.16M-4.5% | -$6.85M-43.0% | -$4.79M-36.9% | ||
| -$11.6M— | —— | $22.12M+258% | -$13.99M-258% | $8.87M+195% | ||
| -$758K-111% | $7M— | $0-100% | $5.16M— | $0-100% | ||
| -$5.93M-215% | $5.18M— | —— | $1.69M+191% | $581K+109% | ||
| $0— | —— | —— | -$139K+96.2% | -$3.68M+13.3% | ||
| —— | $0— | $0— | $0— | $0+100% | ||
| $7.11M-6.8% | $7.63M+0.7% | $7.58M+1.3% | $7.49M+1.5% | $7.38M-1.3% | ||
| -$185K+59.2% | -$453K+71.1% | -$1.57M— | $0+100% | -$149K+73.8% | ||
| -$48K— | —— | -$249K-75.4% | -$142K-18.3% | -$120K— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $108.18M+26.0% | $85.88M— | —— | —— | $0— | ||
| $19K-24.0% | $25K+4.2% | $24K-75.5% | $98K-52.7% | $207K+2.0% | ||
| -$6.76M— | —— | -$400K— | —— | -$5.29M— | ||
| -$2.61M+49.7% | -$5.18M-46.7% | -$3.53M+66.3% | -$10.49M+20.5% | -$13.19M-1,423% | ||
| -$5M+45.3% | -$9.14M-27.7% | -$7.16M-4.5% | -$6.85M-43.0% | -$4.79M-36.9% | ||
| -$48.62M-2.0% | -$47.68M-50.9% | -$31.61M+21.6% | -$40.29M+31.9% | -$59.14M-5.3% | ||
| -$48.62M-2.0% | -$47.68M-50.9% | -$31.61M+21.6% | -$40.29M+31.9% | -$59.14M-5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ginkgo Bioworks generate?
- Ginkgo Bioworks (DNA) generated -$166.2M in operating cash flow over the trailing twelve months.
- What is Ginkgo Bioworks's free cash flow?
- After $2.0M of capital expenditures, Ginkgo Bioworks's free cash flow was -$168.2M over the trailing twelve months, up 51.3% year over year.
- Where does Ginkgo Bioworks's cash flow data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
